San Diego-based ChemDiv Inc. has entered a research collaboration with New Jersey-based Janssen Research & Development LLC to find promising targets that might lead to the development of medicines.
ChemDiv, founded in 1990, is a contract research organization that often does the discovery work big pharmaceutical and biotech companies need to develop new products.
Under the terms of the agreement, Janssen, which has a significant presence in San Diego, is given open-ended access to ChemDiv’s discovery chemistry platform. In return, ChemDiv will receive access fees and will be eligible for undisclosed milestone payments based on successful identification of new targets.
“Opening up highly relevant new chemistry space and expansion of its broad discovery resources has been ChemDiv’s laser focus for the past two decades,” said Ron Demuth, general manager of ChemDiv. “In contrast to traditional unit-pricing models and fee-for-service arrangements common to discovery and synthetic chemistry library procurement, this new economic model minimizes the Janssen cost of acquiring a key research resource, while appropriately rewarding ChemDiv based on the productivity of our chemistry. The arrangement fulfills our goal of helping Janssen, and all our partners, to develop potent medicines and remain at the forefront of drug discovery and development.”
